Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of developing psoriatic arthritis, an inflammatory condition that impacts the ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Statistically, approximately 1 in 4 patients with psoriasis will develop psoriatic arthritis (PsA) in their lifetime. 1 However, it can be difficult to predict which patients will progress to PsA ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

B oth men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)-a chronic inflammatory ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common symptoms of psoriatic arthritis include joint pain, swelling, and stiffness.

Psoriatic arthritis (PsA) is less common among Black people compared to other races, but differences in prevalence may also ...